Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 5% on Insider Selling

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) fell 5% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $22.72 and last traded at $22.80. 263,570 shares changed hands during mid-day trading, an increase of 2% from the average session volume of 257,230 shares. The stock had previously closed at $24.00.

Specifically, COO Anish Patel sold 1,107 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $25.00, for a total value of $27,675.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Enliven Therapeutics news, COO Anish Patel sold 1,107 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $25.00, for a total transaction of $27,675.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Joseph P. Lyssikatos sold 30,000 shares of the company’s stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $25.04, for a total value of $751,200.00. The disclosure for this sale can be found here. Insiders sold a total of 1,291,913 shares of company stock worth $28,611,100 over the last 90 days. Company insiders own 29.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock.

View Our Latest Stock Report on ELVN

Enliven Therapeutics Stock Performance

The company has a market cap of $1.08 billion, a price-to-earnings ratio of -11.87 and a beta of 1.05. The business’s 50 day simple moving average is $19.14 and its 200-day simple moving average is $15.63.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. Research analysts expect that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $2,020,000. Blackstone Inc. acquired a new position in Enliven Therapeutics during the first quarter worth $443,000. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics during the first quarter worth $167,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Enliven Therapeutics during the fourth quarter worth $66,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Read More

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.